Compare iShares MSCI Canada (TSX) (EWC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs GeneDx Holdings Corp — how do they compare? iShares MSCI Canada (TSX) trades at $59.03 (market cap $6.99B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares MSCI Canada (TSX) is far larger — about 3.5× GeneDx Holdings Corp's market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 56 Days and GeneDx Holdings Corp for 19 Days on average.
| EWC | WGS | |
|---|---|---|
Market Cap | $6.99B | $2.02B |
Volume | 1,625,847 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $167.51 |
52-Week Low | $49.72 | $34.51 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $58.32, up 0.66% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Key support is at $58, with resistance at $59. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights trade tensions with the U.S. and Canada's pursuit of EU associate membership, creating uncertainty.
The outlook is clouded by geopolitical risks and lack of financial data. Upside depends on resolving trade disputes, but downside risks from U.S. tariff threats and economic softening in Canada persist. Investors need updated earnings and valuation metrics to assess true potential amid volatile conditions.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
